Experimental Pancreatic Cancer Pill Nearly Doubles Survival in Late-Stage Trial

Revolution Medicines' oral drug daraxonrasib doubled median overall survival to 13.2 months versus 6.7 months for standard chemotherapy in a pivotal pancreatic cancer study.